IMR Press / EJGO / Volume 29 / Issue 1 / pii/1630995333399-1159744736

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
Outcome of uterine clear cell carcinomas compared to endometrioid carcinomas and poorly-differentiated endometrioid carcinomas
Show Less
1 Gynecologic Oncology Service, Centre hospitalier de l’Université de Montréal (CHUM) - Hôpital Notre-Dame, Montréal, Quebec (Canada)
2 Department of Obstetrics and Gynecology, Gynecologic Oncology and Senology Unit, Geneva University Hospitals
3 Geneva Cancer Registry, Institute for Social and Preventive Medicine, Geneva University
4 Department of Radiation Oncology, Geneva University Hospitals
5 Department of Clinical Pathology, Geneva University Hospitals, Geneva (Switzerland)
Eur. J. Gynaecol. Oncol. 2008, 29(1), 57–60;
Published: 10 February 2008

Objectives: Our aim was to compare the survival between patients with clear cell carcinoma (CC) and patients with endometrioid carcinoma (EC). Methods: Through the population-based Geneva Cancer Registry, we identified 1,380 resident women diagnosed with uterine cancer between 1970 and 2000. We excluded those with papillary serous endometrial carcinoma and uterine sarcomas. We categorized patients as CC (n = 32, 2.8%) or EC (n = 1,145, 97.2%). Uterine cancer-specific survival rates were calculated by Kaplan-Meier analysis. We used Cox proportional hazards analysis to compare uterine cancer mortality risks between groups, and adjusted these risks for other prognostic factors. Results: CC patients presented with a more advanced stage at diagnosis than EC patients (p = 0.002). Compared to women with EC, women with CC had a significantly greater risk of dying from their disease (hazard ratio [HR] 2.9, 95% confidence interval (95% CI) 1.7-4.9). After adjustment for age, stage and adjuvant chemotherapy, the risk of dying from uterine cancer was still significantly higher for CC patients (HR 2.0, 95% CI 1.2-3.4). By univariate analysis, the risk of dying of endometrial cancer was not significantly higher in CC patients than in patients with poorly-differentiated EC (HR 1.3, 95% CI 0.7-2.3). Conclusion: This population-based investigation shows that patients with CC have a poorer outcome than those with EC. Studies to determine the role of adjuvant treatment in CC patients are needed.
Adjuvant chemotherapy
Endometrioid carcinoma
Clear cell carcinoma
Back to top